Home › ARCA Biopharma Announces IND Submission To US FDA For Gencaro For The Treatment Of Atrial Fibrillation
 

Keywords :   


ARCA Biopharma Announces IND Submission To US FDA For Gencaro For The Treatment Of Atrial Fibrillation

2013-10-30 03:30:20| drugdiscoveryonline News Articles

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the GENETIC-AF clinical trial of Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF)

Tags: treatment submission ind announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
15.06Atlantic Tropical Weather Outlook
15.06Eastern North Pacific Tropical Weather Outlook
15.06This Week in Agribusiness, June 15, 2024
15.06Atlantic Tropical Weather Outlook
15.06Eastern North Pacific Tropical Weather Outlook
15.06With Gratitude for a Job Well Done
More »